EUVIMEDEuropean Health Evidence
Uhr 10/10Sources Journal Tree
Easy Demo

EUVIMED Themenbrowser · Onkologie · Seite 62

Was ist neu im Gesundheitswesen?

Entdecken Sie tatsächlich neu veröffentlichte Arbeiten aus Medizin, Pflege, Therapie, Public Health und Life Sciences. Sortiert nach Publikationsdatum, nicht nach Zitierhäufigkeit.

Themen erkunden

Aktuelle Forschung nach Fachgebiet

24 neue Nachweise auf dieser Seite Publiziert in den letzten 30 Tagen Neueste zuerst Crossref DOI
01.09.2026journal-article

Clinical Kidney Journal

Targeting calciphylaxis: the emergence of vitamin K as a potential treatment

Maria Fusaro, Smeetha Sinha, Antonio Bellasi, Markus Ketteler, Carlo Alfieri, Martin H de Borst, Ditte Hansen, Pietro Manuel Ferraro, Juan Miguel Díaz-Tocados, Mathias Haarhaus, Mehmet Kanbay, Maurizio Gallieni, Paolo Simioni, Sandro Giannini, Sharon Huish, Althea Cossettini

Abstract Calciphylaxis, or calcific uraemic arteriolopathy (CUA), is a rare, life-threatening vascular disorder predominantly affecting patients with advanced chronic kidney disease (CKD), especially those on dialysis. It is characterized by arteriolar calcification, thrombosis, and painful ischemic skin lesions that frequently ulcerate, contributing to high morbidity and mortality. Calciphylaxis arises from medial arterial calcification, endothelial injury, and a pro-inflammatory, pro-thrombotic milieu. Disruption …

01.09.2026journal-article

Journal of Biomolecular Techniques

A National Assessment of Cancer Center Shared Resources Metrics: Results from the First NACCSR Survey

Jerry Edward Chipuk, Fei Ye, Jai N. Patel, Steven J. Madore, Crystal F. Kline, Matthew Nowacki, Andrés Chousal Cantú, David S. Goerlitz, Kevin K.C. Lloyd, Jay W. Fox, George S. Grills

Tracking core metrics is a critical component of centralized core facility management and is essential for ensuring that individual cores are efficiently operated, effectively evaluated, and optimally catalyze research. The National Alliance of Cancer Center Shared Resources (NACCSR) is a consortium of shared resource leaders from the National Institutes of Health (NIH) National Cancer Institute (NCI) designated Cancer Centers. The NACCSR Core Metrics Committee (CMC) includes shared resource leaders from a dozen NC …

01.09.2026journal-article

Endocrines

Metabolic Outcome and CV Risk in Breast Cancer Patients

Francesco Carlo Felicetti, Gloria Mittica, Chiara Cavallin, Ester Campus, Elena Laura Salerno, Filippo Gatti, Alessandra Beano, Umberto Ricardi, Emanuela Arvat, Nicoletta Fortunati

Breast cancer [BC] is the most diagnosed cancer among women worldwide. Thanks to advancements in early detection, systemic therapies, and supportive care, survival rates have significantly improved. As more patients survive BC, cardiovascular disease [CVD] has emerged as a leading cause of long-term morbidity and mortality in this population. This is largely due to a combination of shared risk factors, such as obesity, diabetes and metabolic syndrome, combined to cardiotoxic effects of certain anticancer therapies, …

01.09.2026journal-article

International Journal of Cancer

Tibolone Use Associated With Elevated Hepatocellular Carcinoma Risk: Findings From a Nationwide Cohort

Jimin Lee, Hye Jun Kim, Sun Jae Park, Sangwoo Park, Jina Chung, Jiwon Yu, Ju Hyun Kang, Seogsong Jeong, Hyun‐Young Shin, Sang Min Park

ABSTRACT Tibolone, a synthetic steroid with estrogenic, progestogenic, and androgenic activity, is widely prescribed for menopausal symptoms, but its association with hepatocellular carcinoma (HCC) remains unclear. Using data from 117,271 women aged ≥ 45 years in the Korean National Health Insurance Service–Health Screening Cohort, we evaluated tibolone use between 2003 and 2007 and identified incident HCC from 2009 through 2019, implementing a 1‐year lag period. Participants were propensity score–matched (1:10) by …

01.09.2026journal-article

Journal of Oncology Pharmacy Practice

From supportive galenic compounding to advanced clinical pharmacy: A decade of excellence and safety in the Antiblastic Drugs Unit in Southern Italy (2014–2025)

Filomena D'Amico, Rosa Moscogiuri, Loredana Brandi, Francesco Colasuonno, Mariangela Calcagno, Alessandro Maggi, Claudia Ingrosso, Tiziana Guarino, Antonio Ungaro, Vito Gregorio Colacicco, Salvatore Pisconti

Objectives Antiblastic Drugs Units (ADUs) ensure safety, appropriateness and sustainability of oncology treatments. Over the last decade, hospital pharmacists have expanded their role from aseptic compounding to advanced clinical pharmacy. This study describes the ten-year evolution of the ADU of ASL Taranto in Southern Italy, focusing on clinical, organisational and strategic value generated from 2014 to 2025. Methods A retrospective descriptive analysis of activity data, organisational changes and clinical pharma …

02.09.2026journal-article

CNS Neuroscience & Therapeutics

Awake Craniotomy for Eloquent Region Glioblastoma Classified by Tumor Location—A Retrospective and Prospective Cohort Study

Yuzhe Li, Shimeng Weng, Jiahan Dong, Jiangwei Wang, Zhong Zhang, Xing Fan, Yinyan Wang, Wenbin Ma, Tao Jiang, Shengyu Fang

ABSTRACT Introduction The efficacy of awake craniotomy (AC) with intraoperative mapping for glioblastoma (GBM) in eloquent regions remains debated. This study aims to evaluate functional and survival outcomes of GBM patients undergoing AC stratified by tumor locations. Methods A combined retrospective (2015–2023, n = 114: 43 AC vs. 71 standard craniotomy) and prospective cohort (2023–2025, n = 28: 13 AC vs. 15 standard craniotomy) of GBM patients with motor/language‐eloquent tumors was analyzed. Tumors were classif …

03.09.2026journal-article

MedComm

Neoadjuvant PD‐1 Blockade Tislelizumab (BGB‐A317) in Combination With Etoposide and Platinum‐Based Chemotherapy for Limited‐Disease Small Cell Lung Cancer

Shiyue Wan, Shiqi Hu, Yilv Yan, Fenghuan Sun, Dongliang Bian, Jie Luo, Dong Xie, Wenxin He, Liang Duan, Yuming Zhu, Nan Song, Ming Liu, Hongcheng Liu, Gening Jiang, Peng Zhang

ABSTRACT Neoadjuvant immunochemotherapy has transformed treatment paradigms in non–small cell lung cancer, yet its applicability in limited‐disease small cell lung cancer (LD‐SCLC) remains unknown. Here, we report findings from LungMate‐006, the first prospective Phase II trial evaluating PD‐1 blockade with tislelizumab combined with platinum–etoposide in LD‐SCLC. Among 15 enrolled patients, the regimen achieved an objective response rate of 66.7% and enabled curative‐intent surgery in 60% of patients, all with R0 …

01.09.2026journal-article

Nano Research

Reticuloendothelial system blockade-assisted redirection of celastrol-loaded nanomedicine to glomeruli for treatment of mesangioproliferative glomerulonephritis

Jiali Fu, Yujia Wang, Anqi Zhang, Ting Li, Yan Yuan, Kejin Chen, Shanshan He, Lin Li, Shiqi Huang, Ling Guo, Xun Sun, Tao Gong, Ling Zhang, Qing Lin, Zhirong Zhang

Abstract Glomerulonephritis (GN), a major cause of chronic kidney disease, remains difficult to treat due to inefficient glomerular drug delivery following systemic administration. Here, we report a targeted nanotherapeutic strategy based on celastrol (CLT)-loaded, positively charged poly(lactic-co-glycolic acid) (PLGA) nanoparticles (CLT@R8-PLNs) designed to promote glomerular accumulation. To further improve renal targeting, a reticuloendothelial system (RES) blockade strategy was employed by pre-saturating phago …

01.09.2026journal-article

Physics in Medicine & Biology

A multi-scale fusion model based on multi-phase contrast-enhanced CT for predicting pancreatic cancer resectability

Xiaohui Cheng, Yu Liu, Jun Li, Jianhua Ma, Yi Gao, Chenjie Zhou, Shulong Li

Abstract Purpose. Develop a multi-scale fusion model (MSFM) based on multi-phase contrast-enhanced computed tomography (CECT) to predict pancreatic cancer (PC) resectability, thereby assisting expert decision-making. Methods. This retrospective study enrolled 280 patients with PC from four institutions, which were randomly divided into a training cohort (202 patients) and an independent test cohort (78 patients). Three-phase CECT images (arterial, venous, and delayed phases) were used for modeling. The MSFM compris …

01.09.2026journal-article

Non-Coding RNA

microRNAs as Regulators of the Immune Response and Their Potential Therapeutic Applications in Cancer

Ezgi Biltekin, Bulent Ozpolat

MicroRNAs (miRNAs) are small non-coding RNAs that have emerged as critical regulators of gene expression and key cellular processes in cancer, including tumor cell proliferation, survival, metastasis, and both innate and adaptive immune responses within the tumor microenvironment. Through their ability to modulate immune cell development, differentiation, polarization, antigen presentation, cytokine signaling and immune checkpoint expression, miRNAs play a vital role in shaping immune responses and represent attrac …

01.09.2026journal-article

Japanese Journal of Clinical Oncology

A reanalysis of the Hitachi cohort study evaluating the effectiveness of low-dose CT screening for lung cancer

Keisuke Fukui, Takeshi Nawa, Tomio Nakayama, Motoyasu Sagawa

Abstract The effectiveness of low-dose thoracic computed tomography (CT) screening for lung cancer for non-smokers or light smokers has been unclear. The results of the Hitachi cohort study performed by the conventional multivariable analysis suggested the reduction of lung cancer mortality by thoracic CT screening, but also revealed the lower all-cause mortality in the CT group, which indicated the existence of self-selection bias. Because the background of the subjects in the CT screening group and that in the X- …

01.09.2026journal-article

Trends in Urology & Men's Health

The Influence of Prostate Volume on Magnetic Resonance Imaging Diagnostic Performance and the Adjunctive Role of Prostate‐Specific Membrane Antigen Positron Emission Tomography in Detecting Clinically Significant Prostate Cancer

Matthieu Bryan Chun‐Hei Mo, Sachin Joshi, William Harrison, Madeleine Bain, Nikhil Sapre, Devang Desai

ABSTRACT To evaluate the influence of prostate volume on the diagnostic accuracy of multiparametric MRI (mpMRI) in detecting clinically significant prostate cancer (ISUP Grade ≥ 2), using radical prostatectomy (RP) histopathology as the reference standard. A secondary objective was to assess the adjunctive value of PSMA PET in identifying clinically significant cancer in cases where mpMRI findings were negative or low suspicion, particularly in larger prostate volumes. We conducted a multicentred regional observati …

01.09.2026journal-article

Cancer Nursing

A Scoping Review of the Perceptions and Experiences of People From Underserved Groups of Being on Personalized Stratified Follow-Up Following Treatment for Breast Cancer

Katie Sutton, Sophie McGrevey, Verna Lavender, Lorraine Marke, Jo Armes

Background: Personalized Stratified Follow-Up (PSFU) is an approach to cancer follow-up involving patients re-accessing care when they need to, rather than attending predetermined appointments. The benefits of this approach are a more personalized experience for patients and increased capacity in clinics. Objective: To understand the evidence relating to the experiences of people on PSFU following breast cancer treatment, specifically in terms of the perceptions of people from underserved groups. Methods: A scoping …

01.09.2026journal-article

Cell Death Discovery

Concurrent upregulation of autophagic flux and induction of the SQSTM1/p62-VCAM-1 axis deter radiosensitivity of triple-negative breast cancer cells

Nisha Yadav, Anusha Banerjee, Tanzeela, Priya Saha, Nishakumari Chentunarayan Singh, Akanksha Bhardwaj, Manisha Yadav, Suchitra Narayan, Arjun Singh, Neeraj Jain, Seema Gupta, Navin Singh, Madhav Nilakanth Mugale, Teerthraj Verma, Dipak Datta, Kalyan Mitra, Jayanta Sarkar

Abstract Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer (BC) with higher incidence rates in India. Ionizing radiation (IR) is a key component of TNBC treatment regimens. However, overall suboptimal response during the course of multiple repeat radiotherapy with eventual attainment of radioresistance remains a major challenge for this oncologic treatment modality. To overcome this limitation, it is important to understand molecular signatures that drive cells to transfor …

01.09.2026journal-article

Cancer Epidemiology, Biomarkers & Prevention

Mining Stored-Specimen Studies for Information about Cancer Natural History

Jane Lange, Ruth Etzioni

Abstract The advent of new multicancer early detection tests and publication of early diagnostic results have generated expectations of clinical benefit from multicancer screening. The clinical benefit of a cancer screening test depends critically on disease natural history, which is typically learned from prospective screening studies. Retrospective studies of stored blood specimens are important in learning about a test’s preclinical diagnostic performance but have rarely been used to infer natural history. The e …

01.09.2026journal-article

Cancers

MR-Guided Adaptive Radiotherapy in Lung Cancer: Current Landscape and Future Directions

Abrahams Ocanto, Macarena Teja, Daniela Gonsalves, Walter Vásquez, Inmaculada Navarro-Domenech, Marta Moreno-Jimenez, Gloria Guardia, Dulce Urias, Scarlet Crespo, Mariana Temes, Nicolly Hernández, Suresh Senan, Drew Moghanaki, Rosa Morera, Ignacio Azinovic, Javier Luna, Felipe Couñago

Magnetic resonance-guided radiotherapy (MRgRT) delivered with MR-linac technology represents a major advance in lung cancer radiotherapy, enabling daily online adaptive planning based on high-quality soft-tissue visualization, real-time motion assessment, and anatomy-driven treatment personalization. The challenges in lung cancer treatment with conventional radiotherapy delivery due to respiratory motion, inter and intra-fraction anatomical changes make MRgRT capabilities particularly relevant. This narrative revie …

01.09.2026journal-article

Current Bioinformatics

Computational Tools for Identifying Cancer Driver Genes and Mutations: A Comprehensive Review

Ali F. Alsulami

Understanding the genetic basis of cancer requires the accurate identification of driver genes and driver mutations, those alterations that promote tumorigenesis, while distinguishing them from neutral, or passenger, mutations. This review provides a comprehensive overview of computational strategies developed to detect and prioritise cancer drivers at both the gene and mutation levels. The review systematically classifies and compares more than 20 widely used tools, highlighting differences in their conceptual fou …

02.09.2026journal-article

Cancer Research Communications

Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts

Daniël Gorgels, Chao-Chi Wang, Lore De Cock, Luna De Sutter, Karo Wyns, Kimberly Verbeeck, Ulla Vanleeuw, Daphne Hompes, Friedl Sinnaeve, Hazem Wafa, Maria Jose Guillén, Pablo Avilés, Raf Sciot, Agnieszka Wozniak, Patrick Schöffski

Abstract Trabectedin, prototype of the ecteinascidin class of drugs, is a known second- or later-line therapeutic option for advanced soft tissue sarcoma (STS). We evaluated the antitumor activity of two novel synthetic trabectedin derivatives, ecubectedin and PM54, in selected patient-derived xenograft (PDX) STS models. In total, 364 Naval Medical Research Institutenu/nu mice were transplanted bilaterally with two leiomyosarcoma (LMS), two dedifferentiated liposarcoma (DDLPS), one synovial sarcoma (SynSa), and one …

01.09.2026journal-article

Journal of Pure and Applied Microbiology

CRISPR-Based Gene Editing in Human and Animal Health: Revolutionizing Disease Resistance and Treatment

Bandar Aloufi

CRISPR gene-editing technology has revolutionized modern genetics, offering precise and efficient modifications across multiple domains, including human medicine, agriculture, and veterinary science. This study explores the diverse applications of CRISPR, highlighting its role in treating genetic disorders such as sickle cell anemia and Duchenne muscular dystrophy, advancing cancer immunotherapies, and developing CRISPR-based antiviral therapies for HIV and COVID-19. In agriculture, CRISPR has facilitated the devel …

02.09.2026journal-article

Cancer Medicine

QRICH1 Suppresses Glioma Progression by Inducing ER Stress and Activating the PERK ‐ ATF4 ‐ CHOP Pathway

Yunjiang Wang, Min Xu, Zhenglou Chen, Xuqi Huo, Ya Xue, Xiang Ji, Yang Shen, Hongsheng Wang

ABSTRACT Background ER stress (ERS) influences tumor behavior through the unfolded protein response (UPR), yet its role in glioma is not fully defined. This study investigated the function of the ERS‐related regulator QRICH1 in glioma progression. Methods Public databases (TCGA and GTEx) were used to evaluate QRICH1 expression, survival, and prognostic significance in glioma. Lentiviral QRICH1 overexpression or knockdown was established in U87 and U251 cells, followed by functional and mechanistic assays. A subcuta …

01.09.2026journal-article

International Journal of Computer Information Systems and Industrial Management Applications

Experimental Comparison of Microwave and Conventional Heat Treatment for Improving Surface Characteristics of Copper, Titanium, and Silicon Carbide Composites

Kapil Kumar, Rojaleena Das, Nitish Kaushik Publication

Microwave heat treatment is emerging as an energy saving alternative to conventional thermal treatment owing to its fast volumetric heating, short processing time and enhancement in microstructural and mechanical properties of engineering materials. In this paper, the microwave heating efficiency of Copper (Cu), Titanium (Ti) and Silicon Carbide (SiC) composites by powder metallurgy is experimentally studied and compared with conventional heating methods. Composite samples were prepared by uniform powder mixing fol …

02.09.2026journal-article

BMJ Open

Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician’s choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II)

Emma Connolly, Michelle White, Shankar Siva, Mathias Bressel, Adrienne See, Kate Hunter, Jennifer Tan, Vanessa Panettieri, Daphne Day, Keelan Byrne, Amelia McCartney, Kate Webber, Katrina Woodford, Steven David

Introduction Oligoprogressive disease (OPD) is a clinically significant pattern of progression observed in patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer treated with endocrine therapy (ET) and cyclin-dependent kinase (CDK) 4/6 inhibitors. Stereotactic ablative body radiotherapy (SABR) is an emerging strategy that may ablate resistant subclones and prolong the benefit of systemic therapy. The AVATAR-II trial investigates whether the ad …

04.09.2026journal-article

Journal of Obstetrics and Gynaecology Research

Intrathecal Chemotherapy Through Ommaya Reservoir in Leptomeningeal Metastasis From Cervical Cancer: A Rare Case Report and Literature Review

Chery Ahn, Haein Seo, Dongmin Jo, Byeol Han, Eunmi Choi, Sewon Kim, Seo Woo Chung, Ok‐Ju Kang

ABSTRACT Leptomeningeal metastasis (LM) is a rare complication of cervical cancer associated with a poor prognosis. We report a 61‐year‐old woman with stage IVB cervical squamous cell carcinoma who developed acute headache and diplopia during systemic chemotherapy. Brain magnetic resonance imaging suggested LM, which was confirmed by cerebrospinal fluid (CSF) cytology. An Ommaya reservoir was inserted, and intrathecal methotrexate therapy was initiated. The patient showed rapid neurological improvement, normalizati …

04.09.2026journal-article

International Journal of Urology

Distinct Prognostic Roles of Grade Group and Intraductal Carcinoma of the Prostate in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

Junichi Ikeda, Hisanori Taniguchi, Monta Inoue, Yuki Masuo, Takahiro Nakamoto, Makoto Taguchi, Seiji Shimada, Takao Mishima, Masaaki Yanishi, Katsunori Uchida, Hidefumi Kinoshita

ABSTRACT Objectives The study aimed to evaluate the impact of grade group (GG) and intraductal carcinoma of the prostate (IDC‐P), as established prognostic factors, on clinical endpoints in metastatic hormone‐sensitive prostate cancer (mHSPC) patients treated with androgen receptor signaling inhibitors (ARSIs). Methods We retrospectively analyzed 147 patients with mHSPC treated with androgen deprivation therapy and ARSIs (abiraterone acetate, enzalutamide, or apalutamide). Associations between clinicopathological f …